The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

The FDA has approved Merck’s Enflonasia, a monoclonal antibody designed to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The approval is based on data ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

PB2-V/K627 and NP-N52 mutations can be transmitted between guinea pigs and between ferrets via direct contact and respiratory droplet. Highly pathogenic avian influenza is an increasing global ...

Mar. 13, 2025 — A discovery about how severe COVID-19 damages lung cells suggests that an existing drug could treat lingering respiratory problems not just from COVID but influenza and other ...

Respiratory tract diseases are illnesses that affect components of the respiratory system, including the nasal passages, the bronchi and the lungs. They range from acute infections, such as ...